Developer docs
API playgroundTry for free, no card

Search company profiles

Ignis Therapeutics

Full company profile

uuid00024v2

Namestring
Ignis Therapeutics
Legal namestring
翼思生物医药(上海)有限公司
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Ignis Therapeutics (翼思生物) is a Shanghai-based, privately-held CNS-focused biopharmaceutical company founded in December 2020 that operates a full value-chain model covering R&D, clinical development, regulatory registration, manufacturing, supply, and commercialization of innovative therapies for central nervous system diseases across Greater China (mainland China, Hong Kong, Macau, Taiwan). The company pursues a three-axis strategy of in-licensing globally validated CNS assets, co-developing with academic partners, and building a proprietary first-in-class pipeline, targeting ten disease areas including epilepsy, excessive daytime sleepiness, insomnia, Parkinson's disease, migraine, neuropathic pain, ADHD, depression, schizophrenia, and Alzheimer's disease.

Its commercial portfolio is anchored by two NMPA-approved products (December 2025): Cenobamate (翼弗瑞®), a third-generation anti-epileptic with dual mechanism (selective INaP inhibition plus GABAA positive allosteric modulation) licensed from SK Biopharmaceuticals and showing 59.6% seizure-free rate in Chinese Phase III; and Solriamfetol (翼朗清®), a dopamine/norepinephrine reuptake inhibitor for OSA-related excessive daytime sleepiness, also licensed from SK Biopharmaceuticals. A third asset, Monarch eTNS 2.0 (FDA-approved non-drug trigeminal nerve stimulation device for pediatric ADHD), is licensed from NeuroSigma. The proprietary pipeline is led by IGS01, an M4 muscarinic receptor positive allosteric modulator for Parkinson's levodopa-induced dyskinesia positioned as the first-in-class globally, with IND approval in December 2025 and Phase I dosing initiated January 2026. Additional early-stage assets (IGS03, IGS04, IGS05, IGS07) and CAS/ShanghaiTech-licensed antidepressant candidates extend the pipeline into depression, neuropathic pain, and other CNS indications.

The business model combines prescription pharmaceutical sales through Class 3A hospital neurology departments, retail pharmacy channels, and internet hospital platforms — with a strategic Sinopharm Holding (国药控股) distribution agreement providing nationwide supply. Revenue is generated through one-time licensing and royalty structures with global partners plus commercial product sales in Greater China. Manufacturing is supported by a wholly-owned Suzhou subsidiary operating a GMP-certified oral solid dose facility built to NMPA/FDA/EMA standards with approximately 1 billion tablet annual capacity, backed by a $160 million total investment and a Drug Production License granted in August 2025. The company employed 100+ staff as of 2021 and has been incubated and backed by 6 Dimensions Capital (通和毓承) alongside Goldman Sachs, Mubadala, HBM Healthcare Investments, Ruentex Group, KB Investment, and W.T.T. Investment.

Short descriptiontext

Ignis Therapeutics (翼思生物) is a Shanghai-based CNS biopharmaceutical company that in-licenses and develops innovative therapies for epilepsy, sleep disorders, Parkinson's, ADHD, and other brain diseases across Greater China, operating a full value-chain model with two NMPA-approved products and a proprietary first-in-class M4 PAM pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS drug development, Neurological therapeutics, Prescription pharmaceuticals, Central nervous system, Epilepsy treatment
Industry1 code
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
CNS Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical product sales
TypeOne Time License
Description

Revenue generated from the commercialization of licensed-in and self-developed CNS drugs in China. The company sells prescription pharmaceuticals through hospital and pharmacy channels. Products include Cenobamate (翼弗瑞®) for epilepsy and Solriamfetol (翼朗清®) for OSA-related excessive daytime sleepiness.

ignistherapeutics.com
2In-licensing and co-development
TypeLicensing Royalties
Description

Company acquires exclusive rights to innovative CNS assets from global partners (SK Biopharmaceuticals, NeuroSigma) for the Greater China region, handles local clinical development, registration, manufacturing, and commercialization.

ignistherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Prescription pharmaceutical products distributed through hospitals and pharmacies — pricing subject to national reimbursement and procurement negotiations.
ModelOtherBilling cadencePay-as-you-go
Notes

Prescription drug pricing determined through national medical insurance negotiation and hospital procurement (GPO/集中采购) processes. Not publicly disclosed.

ignistherapeutics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1翼弗瑞® (Yifeirui®)
Description

Brand name for Cenobamate (西诺氨酯片), a third-generation anti-epileptic drug approved in China for treating focal seizures in adults.

ignistherapeutics.com
+1 more record
Core offering1 text field

Ignis Therapeutics (翼思生物) develops, manufactures, and commercializes innovative central nervous system (CNS) pharmaceuticals and medical devices targeting epilepsy, excessive daytime sleepiness, Parkinson's disease, ADHD, depression, migraine, and other brain disorders. The company combines in-licensing of globally validated CNS assets (from SK Biopharmaceuticals and NeuroSigma) with proprietary self-developed drug candidates, and operates full value-chain capabilities spanning R&D, clinical development, registration, manufacturing, and commercialization. Commercial products include Cenobamate (翼弗瑞®) for focal epilepsy, Solriamfetol (翼朗清®) for OSA-related excessive daytime sleepiness, and the Monarch eTNS 2.0 medical device for pediatric ADHD.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 59.6% seizure-free rate in Chinese Phase III trial for Cenobamate 400mg in focal epilepsy patients refractory to 1-3 anti-seizure drugs
+5 more records
Product overview1 text field

Ignis Therapeutics (翼思生物) operates as a CNS-focused biopharmaceutical company with a portfolio of licensed-in and self-developed products. The commercialized portfolio includes three approved drugs: 翼弗瑞® (西诺氨酯/Cenobamate), a third-generation anti-epileptic drug; 翼朗清® (盐酸索安非托/Solriamfetol), a wakefulness-promoting agent; and the Monarch eTNS 2.0 medical device for ADHD. Self-developed pipeline includes IGS01 (Phase I), IGS03, IGS05, IGS04, IGS07 for Parkinson's disease, depression, neuropathic pain, and other CNS conditions. The company combines in-licensing, proprietary R&D, and full value-chain capabilities from development through commercialization.

Product and service4 records
1Cenobamate (翼弗瑞® / Yifurui®) Tablets
CategoryAnti-epileptic prescription drug
Description

Third-generation anti-epileptic drug with dual mechanism (selective inhibition of persistent sodium current + positive allosteric modulation of GABAA receptors at non-benzodiazepine sites). Licensed from SK Biopharmaceuticals for the Greater China market. Achieved 59.6% seizure-free rate in China Phase III trial (C035 study) for focal epilepsy patients refractory to 1-3 anti-seizure medications. Previously approved by FDA in 2019 and EMA in 2021.

2Solriamfetol (翼朗清® / Yilangkqing®) Hydrochloride Tablets
CategoryWakefulness-promoting prescription drug
Description

Wakefulness-promoting agent with dual mechanism (dopamine and norepinephrine reuptake inhibitor / DNRI). Provides 1-hour onset and 9-hour duration. Licensed from SK Biopharmaceuticals for the Greater China market. Previously approved by FDA in 2019 and EMA in 2020. ESS score reduced to 6.9 (normal range) after 12 weeks of treatment.

3Monarch eTNS 2.0 System
CategoryNeuromodulation medical device
Description

FDA-approved home medical device using external trigeminal nerve stimulation (eTNS) for treating ADHD in children aged 7-12 not on prescription ADHD medication. The first non-drug, non-stimulant therapy for pediatric ADHD. Licensed from NeuroSigma for the Greater China market (China mainland, Hong Kong, Macau).

4IGS01
CategoryParkinson's disease drug (investigational)
Description

Proprietary small molecule innovative drug - highly selective M4 muscarinic acetylcholine receptor positive allosteric modulator (PAM) for treating levodopa-induced dyskinesia (LID) in Parkinson's disease. Globally first M4 PAM class drug entering registrational clinical development. Global rights owned by Ignis Therapeutics.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-01
Description

Strategic cooperation agreement for product distribution and supply chain services. Sinopharm leverages its nationwide hospital and pharmacy distribution network to support Ignis's product launch and ensure stable nationwide supply for 翼弗瑞® and other commercialized products.

2中国抗癫痫协会 (CAAE — Chinese Association Against Epilepsy)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Strategic cooperation agreement signed October 2025 at the 11th CAAE International Epilepsy Forum. Cooperation covers academic exchange, scientific research, epilepsy center development, diagnostic standardization, and patient care programs to improve seizure-free outcomes.

ignistherapeutics.com
3中国科学院分子细胞科学卓越创新中心 (CAS Molecular Cell Science Center)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-01
Description

Tripartite technology transfer agreement with CAS Molecular Cell Science Center and ShanghaiTech University for novel antidepressant drug R&D. CAS and ShanghaiTech licensed Ignis patents for follow-on drug development, manufacturing and commercialization. Milestone payments total 120 million RMB.

4上海科技大学 (ShanghaiTech University)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-01
Description

Tripartite technology transfer agreement with ShanghaiTech University and CAS for novel antidepressant drug R&D. ShanghaiTech University and CAS licensed Ignis patents for follow-on drug development, manufacturing and commercialization.

ignistherapeutics.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-01-01
Description

Ignis acquired exclusive license for the Monarch eTNS System in Greater China (China mainland, Hong Kong, Macau) for ADHD treatment. The system is FDA-approved as the first non-drug therapy for pediatric ADHD. Deal includes potential other indications and local manufacturing rights. NeuroSigma receives upfront payment, up to $10M in milestone payments, and royalties.

6SK Biopharmaceuticals (SK生物医药)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Ignis and SK Biopharmaceuticals signed long-term strategic cooperation for 6 innovative CNS assets including Cenobamate (epilepsy) and Solriamfetol (wakefulness) for Greater China. Ignis holds exclusive rights for development, registration, local manufacturing and commercialization. SK receives upfront, milestones and royalties. SK is a leading Korean CNS pharma that developed Korea's first FDA-approved CNS drug.

ignistherapeutics.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Belgian global biopharma with a large CNS franchise (Briviact, Vimpat, Keppra for epilepsy; Rystiggo for myasthenia gravis). Larger incumbent with overlapping CNS therapeutic areas but a broader portfolio including immunology and rare diseases.

2SK Biopharmaceuticals
TypeDirect peer
Description

South Korean CNS specialty pharma and Ignis's flagship licensor for 6 CNS assets including Cenobamate and Solriamfetol. Direct comparable: shares the same molecule portfolio (Cenobamate, Solriamfetol) for global markets, runs a CNS-focused business model, and combines proprietary R&D with out-licensing economics.

TypeBroad incumbent
Description

US-based neuroscience-focused biotech with franchises in multiple sclerosis, SMA (Spinraza), and Alzheimer's (Leqembi). Larger incumbent with CNS specialty positioning but more concentrated in neurodegeneration rather than Ignis's broader epilepsy/sleep/Parkinson's ADHD focus.

TypeBroad incumbent
Description

Danish global pharma entirely focused on psychiatry and neurology (Brintellix/Trintellix, Abilify Maintena, Rexulti). Direct therapeutic-area overlap with Ignis on CNS specialty, though Lundbeck operates at global incumbent scale across multiple CNS indications.

TypeDirect peer
Description

US-based CNS specialty pharma focused on epilepsy (Oxtellar XR, Trokendi XR) and ADHD (Qelbree). Closely comparable therapeutic mix and specialty-pharma commercialization model, with pipeline expansion via both proprietary R&D and in-licensing.

6Jiangsu Hengrui Pharmaceuticals
TypeRegional player
Description

China's largest domestic innovative pharma, with growing CNS exposure alongside oncology and other therapeutic areas. Comparable as a major Chinese specialty pharma player expanding into innovative CNS, though with a much broader portfolio.

TypeRegional player
Description

Hong Kong/China-listed innovative pharma with established CNS franchise including Seroquel generic, Rivastigmine patch, and ongoing CNS pipeline development. Comparable as a Chinese CNS-focused pharma with both generic and innovative drug exposure.

TypeDirect peer
Description

Ireland/US-based CNS specialty pharma with leading franchises in narcolepsy/EDS (Xyrem, Sunosi which is the same molecule as Ignis's Solriamfetol) and epilepsy. Direct therapeutic-area overlap with Ignis on wakefulness promotion and seizure disorders, with a similarly narrow specialty pharma model.

TypeEmerging player
Description

Pure-play CNS biotech (Zulresso, Zurzuvae for postpartum depression and MDD). Comparable as a CNS-focused emerging biopharma with a small specialty portfolio, although Sage focuses on psychiatry while Ignis has broader neurology/psychiatry coverage.

TypeRegional player
Description

Major Hong Kong-listed Chinese pharma with a substantial CNS franchise (Oulaining for stroke, butylphthalide) and ongoing pipeline expansion into innovative neurology and psychiatry. Comparable scale and Chinese-market specialty CNS focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks2 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ignis Therapeutics

CNS Pharmaceuticalsignistherapeutics.com

Ignis Therapeutics (翼思生物) is a Shanghai-based CNS biopharmaceutical company that in-licenses and develops innovative therapies for epilepsy, sleep disorders, Parkinson's, ADHD, and other brain diseases across Greater China, operating a full value-chain model with two NMPA-approved products and a proprietary first-in-class M4 PAM pipeline.

What Ignis Therapeutics does

Ignis Therapeutics (翼思生物) is a Shanghai-based, privately-held CNS-focused biopharmaceutical company founded in December 2020 that operates a full value-chain model covering R&D, clinical development, regulatory registration, manufacturing, supply, and commercialization of innovative therapies for central nervous system diseases across Greater China (mainland China, Hong Kong, Macau, Taiwan). The company pursues a three-axis strategy of in-licensing globally validated CNS assets, co-developing with academic partners, and building a proprietary first-in-class pipeline, targeting ten disease areas including epilepsy, excessive daytime sleepiness, insomnia, Parkinson's disease, migraine, neuropathic pain, ADHD, depression, schizophrenia, and Alzheimer's disease.

Its commercial portfolio is anchored by two NMPA-approved products (December 2025): Cenobamate (翼弗瑞®), a third-generation anti-epileptic with dual mechanism (selective INaP inhibition plus GABAA positive allosteric modulation) licensed from SK Biopharmaceuticals and showing 59.6% seizure-free rate in Chinese Phase III; and Solriamfetol (翼朗清®), a dopamine/norepinephrine reuptake inhibitor for OSA-related excessive daytime sleepiness, also licensed from SK Biopharmaceuticals. A third asset, Monarch eTNS 2.0 (FDA-approved non-drug trigeminal nerve stimulation device for pediatric ADHD), is licensed from NeuroSigma. The proprietary pipeline is led by IGS01, an M4 muscarinic receptor positive allosteric modulator for Parkinson's levodopa-induced dyskinesia positioned as the first-in-class globally, with IND approval in December 2025 and Phase I dosing initiated January 2026. Additional early-stage assets (IGS03, IGS04, IGS05, IGS07) and CAS/ShanghaiTech-licensed antidepressant candidates extend the pipeline into depression, neuropathic pain, and other CNS indications.

The business model combines prescription pharmaceutical sales through Class 3A hospital neurology departments, retail pharmacy channels, and internet hospital platforms — with a strategic Sinopharm Holding (国药控股) distribution agreement providing nationwide supply. Revenue is generated through one-time licensing and royalty structures with global partners plus commercial product sales in Greater China. Manufacturing is supported by a wholly-owned Suzhou subsidiary operating a GMP-certified oral solid dose facility built to NMPA/FDA/EMA standards with approximately 1 billion tablet annual capacity, backed by a $160 million total investment and a Drug Production License granted in August 2025. The company employed 100+ staff as of 2021 and has been incubated and backed by 6 Dimensions Capital (通和毓承) alongside Goldman Sachs, Mubadala, HBM Healthcare Investments, Ruentex Group, KB Investment, and W.T.T. Investment.

Ignis Therapeutics firmographics

Firmographics
Name
Ignis Therapeutics
Legal name
翼思生物医药(上海)有限公司
Website
https://ignistherapeutics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Ignis Therapeutics (翼思生物) is a Shanghai-based CNS biopharmaceutical company that in-licenses and develops innovative therapies for epilepsy, sleep disorders, Parkinson's, ADHD, and other brain diseases across Greater China, operating a full value-chain model with two NMPA-approved products and a proprietary first-in-class M4 PAM pipeline.
Ownership category
akta.pro rank

Ignis Therapeutics industry classification

Industry
Product category
CNS Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Pharmaceutical Preparations (2834), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • CNS drug development
  • Neurological therapeutics
  • Prescription pharmaceuticals
  • Central nervous system
  • Epilepsy treatment

Where Ignis Therapeutics is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices3 records

Markets served

Ignis Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Pharmaceutical product sales: Revenue generated from the commercialization of licensed-in and self-developed CNS drugs in China. The company sells prescription pharmaceuticals through hospital and pharmacy channels. Products include Cenobamate (翼弗瑞®) for epilepsy and Solriamfetol (翼朗清®) for OSA-related excessive daytime sleepiness.
  2. In-licensing and co-development: Company acquires exclusive rights to innovative CNS assets from global partners (SK Biopharmaceuticals, NeuroSigma) for the Greater China region, handles local clinical development, registration, manufacturing, and commercialization.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPrescription pharmaceutical products distributed through hospitals and pharmacies — pricing subject to national reimbursement and procurement negotiations.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Ignis Therapeutics product offering

Product offering

Core offering

Ignis Therapeutics (翼思生物) develops, manufactures, and commercializes innovative central nervous system (CNS) pharmaceuticals and medical devices targeting epilepsy, excessive daytime sleepiness, Parkinson's disease, ADHD, depression, migraine, and other brain disorders. The company combines in-licensing of globally validated CNS assets (from SK Biopharmaceuticals and NeuroSigma) with proprietary self-developed drug candidates, and operates full value-chain capabilities spanning R&D, clinical development, registration, manufacturing, and commercialization. Commercial products include Cenobamate (翼弗瑞®) for focal epilepsy, Solriamfetol (翼朗清®) for OSA-related excessive daytime sleepiness, and the Monarch eTNS 2.0 medical device for pediatric ADHD.

Product overview

Ignis Therapeutics (翼思生物) operates as a CNS-focused biopharmaceutical company with a portfolio of licensed-in and self-developed products. The commercialized portfolio includes three approved drugs: 翼弗瑞® (西诺氨酯/Cenobamate), a third-generation anti-epileptic drug; 翼朗清® (盐酸索安非托/Solriamfetol), a wakefulness-promoting agent; and the Monarch eTNS 2.0 medical device for ADHD. Self-developed pipeline includes IGS01 (Phase I), IGS03, IGS05, IGS04, IGS07 for Parkinson's disease, depression, neuropathic pain, and other CNS conditions. The company combines in-licensing, proprietary R&D, and full value-chain capabilities from development through commercialization.

Differentiator

Problem solved

Functional benefit

Brands

  • 翼弗瑞® (Yifeirui®): Brand name for Cenobamate (西诺氨酯片), a third-generation anti-epileptic drug approved in China for treating focal seizures in adults.
  • 翼朗清® (Yilangqing®)

Products and services

  • Cenobamate (翼弗瑞® / Yifurui®) Tablets Third-generation anti-epileptic drug with dual mechanism (selective inhibition of persistent sodium current + positive allosteric modulation of GABAA receptors at non-benzodiazepine sites). Licensed from SK Biopharmaceuticals for the Greater China market. Achieved 59.6% seizure-free rate in China Phase III trial (C035 study) for focal epilepsy patients refractory to 1-3 anti-seizure medications. Previously approved by FDA in 2019 and EMA in 2021.
  • Solriamfetol (翼朗清® / Yilangkqing®) Hydrochloride Tablets Wakefulness-promoting agent with dual mechanism (dopamine and norepinephrine reuptake inhibitor / DNRI). Provides 1-hour onset and 9-hour duration. Licensed from SK Biopharmaceuticals for the Greater China market. Previously approved by FDA in 2019 and EMA in 2020. ESS score reduced to 6.9 (normal range) after 12 weeks of treatment.
  • Monarch eTNS 2.0 System FDA-approved home medical device using external trigeminal nerve stimulation (eTNS) for treating ADHD in children aged 7-12 not on prescription ADHD medication. The first non-drug, non-stimulant therapy for pediatric ADHD. Licensed from NeuroSigma for the Greater China market (China mainland, Hong Kong, Macau).
  • IGS01 Proprietary small molecule innovative drug - highly selective M4 muscarinic acetylcholine receptor positive allosteric modulator (PAM) for treating levodopa-induced dyskinesia (LID) in Parkinson's disease. Globally first M4 PAM class drug entering registrational clinical development. Global rights owned by Ignis Therapeutics.

Quantifiable outcome

  • 59.6% seizure-free rate in Chinese Phase III trial for Cenobamate 400mg in focal epilepsy patients refractory to 1-3 anti-seizure drugs
  • +5 more outcomes

Companies that use Ignis Therapeutics

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Ignis Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ignis Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and flagship.

  • 国药控股 (Sinopharm Holding)coreChannel Partner/ Reseller/ Distributor · 1 February 2026Strategic cooperation agreement for product distribution and supply chain services. Sinopharm leverages its nationwide hospital and pharmacy distribution network to support Ignis's product launch and ensure stable nationwide supply for 翼弗瑞® and other commercialized products.
  • 中国抗癫痫协会 (CAAE — Chinese Association Against Epilepsy)coreStrategic or Co-development Partner · 1 October 2025Strategic cooperation agreement signed October 2025 at the 11th CAAE International Epilepsy Forum. Cooperation covers academic exchange, scientific research, epilepsy center development, diagnostic standardization, and patient care programs to improve seizure-free outcomes.
  • 中国科学院分子细胞科学卓越创新中心 (CAS Molecular Cell Science Center)coreStrategic or Co-development Partner · 1 November 2023Tripartite technology transfer agreement with CAS Molecular Cell Science Center and ShanghaiTech University for novel antidepressant drug R&D. CAS and ShanghaiTech licensed Ignis patents for follow-on drug development, manufacturing and commercialization. Milestone payments total 120 million RMB.
  • 上海科技大学 (ShanghaiTech University)coreStrategic or Co-development Partner · 1 November 2023Tripartite technology transfer agreement with ShanghaiTech University and CAS for novel antidepressant drug R&D. ShanghaiTech University and CAS licensed Ignis patents for follow-on drug development, manufacturing and commercialization.
  • NeuroSigmacoreOEM/ Whitelabel/ Licensing Partner · 1 January 2022Ignis acquired exclusive license for the Monarch eTNS System in Greater China (China mainland, Hong Kong, Macau) for ADHD treatment. The system is FDA-approved as the first non-drug therapy for pediatric ADHD. Deal includes potential other indications and local manufacturing rights. NeuroSigma receives upfront payment, up to $10M in milestone payments, and royalties.
  • SK Biopharmaceuticals (SK生物医药)flagshipStrategic or Co-development Partner · 1 November 2021Ignis and SK Biopharmaceuticals signed long-term strategic cooperation for 6 innovative CNS assets including Cenobamate (epilepsy) and Solriamfetol (wakefulness) for Greater China. Ignis holds exclusive rights for development, registration, local manufacturing and commercialization. SK receives upfront, milestones and royalties. SK is a leading Korean CNS pharma that developed Korea's first FDA-approved CNS drug.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Ignis Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • UCB: Belgian global biopharma with a large CNS franchise (Briviact, Vimpat, Keppra for epilepsy; Rystiggo for myasthenia gravis). Larger incumbent with overlapping CNS therapeutic areas but a broader portfolio including immunology and rare diseases.
  • Biogen: US-based neuroscience-focused biotech with franchises in multiple sclerosis, SMA (Spinraza), and Alzheimer's (Leqembi). Larger incumbent with CNS specialty positioning but more concentrated in neurodegeneration rather than Ignis's broader epilepsy/sleep/Parkinson's ADHD focus.
  • Lundbeck: Danish global pharma entirely focused on psychiatry and neurology (Brintellix/Trintellix, Abilify Maintena, Rexulti). Direct therapeutic-area overlap with Ignis on CNS specialty, though Lundbeck operates at global incumbent scale across multiple CNS indications.

Direct peers

  • SK Biopharmaceuticals: South Korean CNS specialty pharma and Ignis's flagship licensor for 6 CNS assets including Cenobamate and Solriamfetol. Direct comparable: shares the same molecule portfolio (Cenobamate, Solriamfetol) for global markets, runs a CNS-focused business model, and combines proprietary R&D with out-licensing economics.
  • Supernus Pharmaceuticals: US-based CNS specialty pharma focused on epilepsy (Oxtellar XR, Trokendi XR) and ADHD (Qelbree). Closely comparable therapeutic mix and specialty-pharma commercialization model, with pipeline expansion via both proprietary R&D and in-licensing.
  • Jazz Pharmaceuticals: Ireland/US-based CNS specialty pharma with leading franchises in narcolepsy/EDS (Xyrem, Sunosi which is the same molecule as Ignis's Solriamfetol) and epilepsy. Direct therapeutic-area overlap with Ignis on wakefulness promotion and seizure disorders, with a similarly narrow specialty pharma model.

Regional players

  • Jiangsu Hengrui Pharmaceuticals: China's largest domestic innovative pharma, with growing CNS exposure alongside oncology and other therapeutic areas. Comparable as a major Chinese specialty pharma player expanding into innovative CNS, though with a much broader portfolio.
  • Luye Pharma Group: Hong Kong/China-listed innovative pharma with established CNS franchise including Seroquel generic, Rivastigmine patch, and ongoing CNS pipeline development. Comparable as a Chinese CNS-focused pharma with both generic and innovative drug exposure.
  • CSPC Pharmaceutical Group: Major Hong Kong-listed Chinese pharma with a substantial CNS franchise (Oulaining for stroke, butylphthalide) and ongoing pipeline expansion into innovative neurology and psychiatry. Comparable scale and Chinese-market specialty CNS focus.

Emerging players

  • Sage Therapeutics: Pure-play CNS biotech (Zulresso, Zurzuvae for postpartum depression and MDD). Comparable as a CNS-focused emerging biopharma with a small specialty portfolio, although Sage focuses on psychiatry while Ignis has broader neurology/psychiatry coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights7 records

Customer concentration

Ignis Therapeutics compliance and trust

Trust signal

Compliance1 record

Ignis Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ignis Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Ignis Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Ignis Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ignis Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ignis Therapeutics

What does Ignis Therapeutics do?

Ignis Therapeutics (翼思生物) develops, manufactures, and commercializes innovative central nervous system (CNS) pharmaceuticals and medical devices targeting epilepsy, excessive daytime sleepiness, Parkinson's disease, ADHD, depression, migraine, and other brain disorders. The company combines in-licensing of globally validated CNS assets (from SK Biopharmaceuticals and NeuroSigma) with proprietary self-developed drug candidates, and operates full value-chain capabilities spanning R&D, clinical development, registration, manufacturing, and commercialization. Commercial products include Cenobamate (翼弗瑞®) for focal epilepsy, Solriamfetol (翼朗清®) for OSA-related excessive daytime sleepiness, and the Monarch eTNS 2.0 medical device for pediatric ADHD.

Is Ignis Therapeutics a public or private company?

Ignis Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ignis Therapeutics founded?

Ignis Therapeutics was founded in 2020. It employs 51 to 100 people.

Where is Ignis Therapeutics based?

Ignis Therapeutics is headquartered in Shanghai, China, in the Asia region.

How does Ignis Therapeutics make money?

Two revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are in-licensing and co-development.

Who are Ignis Therapeutics's main competitors?

Broad incumbents on record are UCB, Biogen and Lundbeck. Direct peers are SK Biopharmaceuticals, Supernus Pharmaceuticals and Jazz Pharmaceuticals. Regional players are Jiangsu Hengrui Pharmaceuticals, Luye Pharma Group and CSPC Pharmaceutical Group. Sage Therapeutics is listed as an emerging player.

Does Ignis Therapeutics have an API?

No public API is recorded for Ignis Therapeutics.

What industry is Ignis Therapeutics in?

Ignis Therapeutics's product category is CNS Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Korea HeraldSK Biopharma launches epilepsy drug in ChinaSK Biopharmaceuticals has officially launched its in-house developed epilepsy drug Cenobamate (marketed as Yifurui) in China after receiving approval from the National Medical Products Administration in December. The drug targets partial-onset seizures in adult patients and initial prescriptions have begun at major hospitals across the country. Development and commercialization are handled by Ignis Therapeutics, a joint venture in which SK Biopharmaceuticals holds a 32.8 percent stake, with distribution facilitated through a strategic agreement with Sinopharm, China's largest pharmaceutical distributor.Medical Device NetworkMonarch eTNS System, USNeuroSigma’s Monarch eTNS system is a bioelectronic medical device approved for treating paediatric ADHD, having received US FDA clearance in April 2019. The company has expanded its commercial reach through partnerships, including an exclusive rights agreement with Ignis Therapeutics for the Chinese market and distribution support from Quick Care Pharmacy in the US.The Pharma LetterIgnis Therapeutics and STADA partner on apomorphine in ChinaIgnis Therapeutics and STADA's Britannia Pharmaceuticals signed an exclusive licensing agreement to develop and commercialize subcutaneous apomorphine for Parkinson's disease in mainland China, Hong Kong, and Macau. Britannia will receive an undisclosed upfront payment, milestone payments, and sales-based royalties, with further terms not disclosed.GlobeNewswireIgnis Therapeutics Licenses NeuroSigma eTNS Technology forIgnis Therapeutics acquired exclusive rights to NeuroSigma's FDA-approved Monarch eTNS System for ADHD in China, Hong Kong, and Macau. The deal includes an upfront payment and up to $10 million in milestone payments, with potential expansion to other indications and manufacturing rights.GlobeNewswireIgnis Therapeutics Licenses NeuroSigma eTNS Technology forIgnis Therapeutics has acquired the exclusive license for NeuroSigma’s FDA-approved Monarch eTNS System to treat ADHD in China, including Hong Kong and Macau. In exchange for these rights, NeuroSigma will receive a significant upfront payment, up to $10 million in milestone payments, and royalties. This agreement marks the launch of the device-based non-drug therapy in the Chinese market, with plans for initial deployment followed by further iterations.BioSpaceIgnis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing TransactionIgnis Therapeutics has acquired the exclusive license to develop and commercialize NeuroSigma’s FDA-approved Monarch eTNS System for treating ADHD in China, including Hong Kong and Macau. The agreement involves a significant upfront payment, up to $10 million in milestone payments, and royalties for NeuroSigma. This transaction marks a strategic expansion for Ignis into bioelectronic therapies while providing NeuroSigma with access to the Chinese market.BioWorldIgnis Therapeutics co-launched by SK, 6 Dimensions with $180M series ASK Biopharmaceuticals and 6 Dimensions co-launched Ignis Therapeutics, a Shanghai-based CNS biotech, with a $180 million series A round led by 6 Dimensions Capital. The financing was the largest series A in China's biopharma industry in 2021, with participation from KB Investment, WTT, HBM Healthcare, and Goldman Sachs.